As of 2026-08-03, the Relative Valuation of Neovacs SA (ALNEV.PA) is (310.78) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.73 EUR, the upside of Neovacs SA based on Relative Valuation is -42672.4%.
The range of the Relative Valuation is (276.93) - (458.95) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 16.5x | 11.7x |
| Forward P/E multiples | 10.0x - 16.6x | 10.7x |
| Fair Price | (276.93) - (458.95) | (310.78) |
| Upside | -38035.1% - -62970.4% | -42672.4% |
| Date | P/E |
| 2026-07-31 | -0.03 |
| 2026-07-30 | -0.03 |
| 2026-07-29 | -0.03 |
| 2026-07-28 | -0.03 |
| 2026-07-27 | -0.03 |
| 2026-07-24 | -0.03 |
| 2026-07-23 | -0.03 |
| 2026-07-22 | -0.03 |
| 2026-07-21 | -0.03 |
| 2026-07-20 | -0.03 |
| 2026-07-17 | -0.03 |
| 2026-07-16 | -0.04 |
| 2026-07-15 | -0.04 |
| 2026-07-14 | -0.04 |
| 2026-07-13 | -0.04 |
| 2026-07-10 | -0.04 |
| 2026-07-09 | -0.05 |
| 2026-07-08 | -0.04 |
| 2026-07-07 | -0.05 |
| 2026-07-06 | -0.05 |
| 2026-07-03 | -0.05 |
| 2026-07-02 | -0.06 |
| 2026-07-01 | -0.05 |
| 2026-06-30 | -0.04 |
| 2026-06-29 | -0.05 |
| 2026-06-26 | -0.05 |
| 2026-06-23 | -0.07 |
| 2026-06-22 | -0.07 |
| 2026-06-18 | -0.07 |
| 2026-06-17 | -0.07 |
| 2026-06-16 | -0.07 |
| 2026-06-15 | -0.07 |
| 2026-06-12 | -0.07 |
| 2026-06-11 | -0.07 |
| 2026-06-10 | -0.07 |
| 2026-06-09 | -0.07 |
| 2026-06-08 | -0.07 |
| 2026-06-05 | -0.07 |
| 2026-06-04 | -0.07 |
| 2026-06-03 | -0.07 |
| 2026-06-02 | -0.14 |
| 2026-06-01 | -0.14 |
| 2026-05-29 | -0.07 |
| 2026-05-28 | -0.07 |
| 2026-05-27 | -0.07 |
| 2026-05-26 | -0.07 |
| 2026-05-25 | -0.07 |
| 2026-05-22 | -0.07 |
| 2026-05-21 | -0.14 |
| 2026-05-20 | -0.07 |